The understanding of the molecular pathogenesis of thyroid cancers paved the way for the development of novel cutting-edge therapeutic agents; for this reason, a more tailored disease management will be possible.Thyroid cancer is the most prevalent neoplasm among endocrine tumors, presenting an increasing incidence trend over the last few years. Multikinase inhibitors have shown improved clinical outcome and implemented tumor response in advanced thyroid cancer. Cancer is still an enigmatic, complex, heterogeneous, rapidly evolving, rapidly shifting, fast adapting and unfortunately not completely understood enemy.
|Titolo:||Targeted agents for advanced thyroid cancer: "knowledge is power"- the role of multikinase inhibitors|
|Data di pubblicazione:||2014|
|Appare nelle tipologie:||Articolo su Rivista|